Germline Panel – Renal Cancer

Test Code
SLS161007
Book Now

What is the Germline Panel - Renal Cancer?

Hereditary kidney cancers account for approximately 5–8% of all renal cancer cases. Conditions such as von Hippel-Lindau (VHL) disease, hereditary leiomyomatosis and renal cell cancer (HLRCC), Birt-Hogg-Dubé syndrome, and tuberous sclerosis complex can predispose individuals to kidney tumors at a young age. Genetic testing helps guide early intervention and personalized treatment strategies.

The Germline Panel – Renal Cancer screens for inherited mutations linked to hereditary kidney cancer syndromes, such as Von Hippel-Lindau (VHL) syndrome and hereditary papillary renal cell carcinoma.

Genes Covered/No of Genes: FH, FLCN, MET, TSC1,TSC2, VHL, WT1

Indications for Testing

  • Individuals diagnosed with early-onset or bilateral kidney cancer.
  • Patients with a family history of renal cancer syndromes.
  • Those with associated symptoms (e.g., hemangioblastomas, skin fibrofolliculomas).

Inheritance Pattern

  • Autosomal dominant for most genes, including VHL, MET, FH, and FLCN.
  • TSC1 and TSC2 mutations cause tuberous sclerosis complex, also inherited in an autosomal dominant manner.

Why is This Test Important?

Genetic findings can guide surveillance, surgical planning, and systemic therapy selection for renal cancer.
Renal Cancer

Contact Us